Free Trial
NASDAQ:APGE

Apogee Therapeutics Q3 2024 Earnings Report

Apogee Therapeutics logo
$35.57 -3.82 (-9.70%)
Closing price 05/6/2025 04:00 PM Eastern
Extended Trading
$35.53 -0.04 (-0.10%)
As of 05/6/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics EPS Results

Actual EPS
-$0.86
Consensus EPS
-$0.73
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A

Apogee Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Apogee Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Apogee Therapeutics' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Apogee Therapeutics Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Apogee Therapeutics: Engineering Biologic Dominance
Apogee Therapeutics price target lowered to $78 from $80 at BofA
See More Apogee Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apogee Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your email.

About Apogee Therapeutics

Apogee Therapeutics (NASDAQ:APGE), through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

View Apogee Therapeutics Profile

More Earnings Resources from MarketBeat